EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Updated Meta-Analysis of Left Atrial Appendage Closure Versus Oral Anticoagulation to Prevent Stroke in Atrial Fibrillation

Prince K Pekyi-Boateng iD, Arankesh Mahadevan, Smith Kofi Frimpong, Lilly Kanishka, Stephen Gbekor iD, Hamilton Abimbilla iD, Brian Jose Villafuerte Trisolini iD, George Akyea Blankson iD, Patrick Deladem Pekyi-Boateng, Dan Youg Nguyen, Omid Shoraka iD, Jana Wold iD und 8 weitere

Stroke · 2026

DOI: 10.1161/strokeaha.126.057089 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Stroke, 2026. Verfasst von Prince K Pekyi-Boateng und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology (P.K.P.-B., A.M., L.K., J.W., A.S., S.L., J.J.M.), University of Utah School of Medicine, Salt Lake City. Hauptthemen laut MEDLINE: Anticoagulants, Atrial Appendage, Atrial Fibrillation, Left Atrial Appendage Closure. Die Arbeit nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Ninety percent of left atrial thrombi in nonvalvular atrial fibrillation arise in the left atrial appendage, which can be occluded percutaneously (left atrial appendage closure [LAAC]). Two 2026 trials (CHAMPION-AF [Watchman Flx Versus Non-Vitamin K Antagonist Oral Anticoagulant for Embolic Protection in the Management of Patients With Non-Valvular Atrial Fibrillation] and CLOSURE-AF [Left Atrial Appendage Closure in Patients With Atrial Fibrillation Compared to Medical Therapy]) more than doubled the available randomized evidence comparing LAAC with oral anticoagulation. We evaluated pooled effects of LAAC on stroke, bleeding, and mortality by bleeding risk, anticoagulation eligibility, and comparator. METHODS: In this systematic review and meta-analysis, we searched PubMed, Scopus, and Embase from inception to April 15, 2026, for randomized controlled trials comparing percutaneous LAAC with oral anticoagulation in nonvalvular atrial fibrillation. Risk of bias was assessed with the Cochrane Risk of Bias 2 tool. Cumulative-incidence outcomes were pooled as odds ratios using random-effects models, with prediction intervals, prespecified subgroups, and trial sequential analysis. RESULTS: Six randomized controlled trials (2014–2026; 358 sites in North America, Europe, and Asia; 7028 patients) compared LAAC with warfarin (2 trials) or a direct oral anticoagulant (4 trials); populations were predominantly anticoagulation-eligible with low prior-stroke prevalence, plus 2 high-bleeding-risk and 1 postablation trial. Overall stroke rates were similar between arms (odds ratio, 1.10 [95% CI, 0.78–1.56]). Ischemic stroke was more frequent with LAAC (odds ratio, 1.41 [95% CI, 1.07–1.86]) but did not reach the required information size. Nonprocedural bleeding was lower with LAAC (odds ratio, 0.58 [95% CI, 0.35–0.96]), the only outcome reaching a sufficient information size, in standard-risk and postablation but not high-bleeding-risk patients. CONCLUSIONS: LAAC is best positioned to reduce nonprocedural bleeding in anticoagulation-eligible patients at standard-to-moderate bleeding risk, rather than as a stroke-equivalent substitute for oral anticoagulation. REGISTRATION: URL: https://www.crd.york.ac.uk/PROSPERO/ ; Unique identifier: CRD420261370546.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsAtrial AppendageAtrial FibrillationLeft Atrial Appendage ClosureStrokeHumansAdministration, OralRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

atrial fibrillationhemorrhagic riskischemic strokeleft atrial appendageoral anticoagulation

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Department of Neurology (P.K.P.-B., A.M., L.K., J.W., A.S., S.L., J.J.M.), University of Utah School of Medicine, Salt Lake City.
  • Department of Internal Medicine (S.K.F.), Geisinger Wyoming Valley Medical Center, Wilkes-Barre, PA.
  • Department of Internal Medicine, UNC Health Blue Ridge Hospital, Morganton, NC (S.G.).
  • Department of Internal Medicine, St. Patrick's Hospital, Offinso, Ghana (H.A.).
  • Department of Neurology, HCA Florida Kendall Hospital, Miami (B.J.V.T.).
  • Department of Internal Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, OH (G.A.B.).

ORCID-Profile: Prince K Pekyi-Boateng, Stephen Gbekor, Hamilton Abimbilla, Brian Jose Villafuerte Trisolini, George Akyea Blankson, Omid Shoraka, Jana Wold, Aaron Shoskes, Stephanie Lyden, Pugazhendhi Vijayaraman, Jaydevsinh Dolia, Jennifer J Majersik, Anwar Tandar, Karol P Budohoski, Ramesh Grandhi

Zitieren

APA

Pekyi-Boateng, P. K., Mahadevan, A., Frimpong, S. K., Kanishka, L., Gbekor, S., Abimbilla, H., Villafuerte Trisolini, B. J., Blankson, G. A., Pekyi-Boateng, P. D., Nguyen, D. Y., Shoraka, O., Wold, J., Shoskes, A., Lyden, S., Vijayaraman, P., Dolia, J., Majersik, J. J., Tandar, A., Budohoski, K. P., & Grandhi, R. (2026). Updated Meta-Analysis of Left Atrial Appendage Closure Versus Oral Anticoagulation to Prevent Stroke in Atrial Fibrillation. Stroke. https://doi.org/10.1161/strokeaha.126.057089

Vancouver

Pekyi-Boateng PK, Mahadevan A, Frimpong SK, Kanishka L, Gbekor S, Abimbilla H, et al. Updated Meta-Analysis of Left Atrial Appendage Closure Versus Oral Anticoagulation to Prevent Stroke in Atrial Fibrillation. Stroke. 2026. doi:10.1161/strokeaha.126.057089

BibTeX
@article{PekyiBoateng2026,
  author = {Pekyi-Boateng, Prince K and Mahadevan, Arankesh and Frimpong, Smith Kofi and Kanishka, Lilly and Gbekor, Stephen and Abimbilla, Hamilton and Villafuerte Trisolini, Brian Jose and Blankson, George Akyea and Pekyi-Boateng, Patrick Deladem and Nguyen, Dan Youg and Shoraka, Omid and Wold, Jana and Shoskes, Aaron and Lyden, Stephanie and Vijayaraman, Pugazhendhi and Dolia, Jaydevsinh and Majersik, Jennifer J and Tandar, Anwar and Budohoski, Karol P and Grandhi, Ramesh},
  title = {Updated Meta-Analysis of Left Atrial Appendage Closure Versus Oral Anticoagulation to Prevent Stroke in Atrial Fibrillation},
  journal = {Stroke},
  year = {2026},
  doi = {10.1161/strokeaha.126.057089}
}
Kostenlos starten →